Caplin Steriles Limited (Caplin), a Subsidiary Company of Caplin Point Laboratories Limited has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ketorolac tromethamine Ophthalmic Solution 0.5% (eye drops), a generic therapeutic equivalent version of (RLD), ACULAR Ophthalmic Solution of Allergan Inc. Ketorolac tromethamine Ophthalmic Solution 0.5% is a nonsteroidal, anti- inflammatory indicated for the treatment of inflammation following cataract surgery and for the temporary relief of ocular itching due to seasonal allergic conjunctivitis. According to IQVIATM (IMS Health), Ketorolac tromethamine Ophthalmic Solution 0.5% had US sales of approximately $36 million for the 12-month period ending December 2023.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,305 INR | +1.90% | -0.44% | -3.76% |
05-06 | Caplin Point Laboratories Gets Colombian Drug Regulator's Approval for Soft Gel Capsules Unit in India | MT |
04-16 | Caplin Point Arm Gets US FDA Final Nod for Ofloxacin Ophthalmic Solution | MT |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-3.76% | 1.16B | |
+20.72% | 43.27B | |
+25.28% | 22.92B | |
+19.18% | 15.43B | |
+13.26% | 12.95B | |
+43.85% | 11.83B | |
-7.79% | 6.91B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+13.13% | 5.55B |
- Stock Market
- Equities
- CAPLIPOINT Stock
- News Caplin Point Laboratories Limited
- Caplin Steriles Limited, A Subsidiary of Caplin Point Laboratories Limited Gets USFDA Approval for Ketorolac Tromethamine Ophthalmic Solution